Biopeak Raises $2.7M for AI Longevity Care

Health-tech startup Biopeak has raised $2.7 million in a follow-on round led by NKSquared, the investment vehicle of Zerodha cofounder Nikhil Kamath. This marks Kamath’s second investment in Biopeak, after he previously invested $1.43 million into the health optimisation startup in August 2024.

For the health-tech ecosystem, this round stands out because it’s not just another “wellness” cheque—it backs a full-stack, clinic-plus-diagnostics model that treats longevity as an ongoing service rather than a one-time test. Biopeak is positioning itself at the intersection of preventive healthcare, advanced diagnostics, and applied AI, which is exactly where a large portion of India’s next health-tech wave is likely to be built.

From the lens of the ai world organisation, this is also a practical example of how AI is moving beyond demos into real-world programmes where outcomes depend on a combination of clinical discipline, data quality, and consistent follow-through. It’s the kind of applied, grounded innovation we spotlight through ai world organisation events, including the ai world summit, as part of our broader focus on responsible adoption and real impact.

Where the money goes: clinics, diagnostics, and proprietary AI

Biopeak said the capital will be used to expand operations, including a new clinic, and to strengthen its diagnostics, proprietary AI tools, research initiatives, and clinical programmes. In other words, the funding is aimed at scaling both the physical footprint (clinics) and the core engine (testing, analysis, and clinical workflows).

In longevity-focused care, expansion is rarely just about opening doors in a new neighbourhood; it’s about making sure the care pathway remains consistent as you add more clients, more clinicians, more tests, and more long-term follow-ups. That’s where proprietary AI tools can matter—when they standardize how insights are surfaced, how risk is tracked over time, and how programmes stay personalized without becoming chaotic at scale.

Biopeak’s next phase—new clinic capacity plus deeper product and research investment—also reflects a broader shift: people are increasingly paying for structured, ongoing preventive care because they want measurable progress, not generic advice. That’s a key storyline we expect to keep coming up in ai conferences by ai world, especially in sessions where founders and operators compare what “AI-enabled healthcare” looks like when it’s deployed responsibly, with humans still accountable for decisions.

Inside Biopeak’s model: a “family health office” for healthspan

Biopeak was co-founded in 2025 by Rishi Pardal and Shiva Subramanian, and it uses AI-driven molecular diagnostics, imaging, and expert-led programmes to optimize healthspan. The company describes a longevity-led “family health office” approach, built around personalized plans aimed at healthspan expansion rather than reactive treatment.

On the diagnostics side, the platform integrates organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythms, and imaging such as MRI, CT, DXA, and ECHO. Biopeak’s in-house clinics then translate these datasets into actionable insights for areas like nutrition, sleep, and stress, delivered through specialized care pathways rather than one-size-fits-all recommendations.

This combination—high-resolution testing, clinical programs, and AI-supported interpretation—is important because longevity services only work when a client can actually act on the insights week after week, month after month. It’s also why many longevity models are building “systems,” not just “reports”: the report is the beginning, but the real value is longitudinal tracking, adherence, and iterative optimization under clinical supervision.

Why this matters for India’s longevity market

Biopeak is based in Bengaluru and targets high achievers, executives, and women, using programmes that combine advanced diagnostics, specialist teams, wearable data, and AI insights tailored to Indian biology and disease patterns. The model emphasizes early risk detection, longitudinal tracking, and interventions designed to improve performance and resilience, which aligns with what many premium preventive-care buyers look for today.

Over the past year, Biopeak says it has grown its client base and clinical offerings amid rising demand for structured longevity services. It opened a clinic in Bengaluru last year and plans to open a second clinic in the coming month, signaling that demand is strong enough to justify physical expansion.

Stepping back, this funding also points to a bigger category trend: preventive health is getting “productized.” Customers increasingly want a well-defined protocol, a repeatable cadence of measurement, and a clear sense of what success looks like—whether that’s better metabolic markers, improved recovery, reduced stress load, or simply fewer surprises over time.

What we’re watching at The AI World Organisation

At the ai world organisation, we track stories like Biopeak because they show how founders are using AI as infrastructure—embedded into diagnostics, workflows, and decision-support—rather than as a surface-level feature. This is exactly the type of applied AI journey that fits the learning agenda at the ai world summit, where operators compare what actually works (and so importantly, what fails) when AI meets real customers, real clinicians, and real constraints.

If you’re building or investing in practical AI—from healthcare and diagnostics to fintech, education, and enterprise automation—our upcoming summit calendar is designed around on-ground adoption and measurable outcomes. The AI World Summit 2026 Asia & Global AI Awards is scheduled for May 28, 2026, in Singapore at Singapore EXPO (1 Expo Drive). The event is positioned as a “Future of AI Summit,” and the page highlights a “5000+ AI Leaders Network” alongside an innovation showcase and awards programming.

For readers following the broader arc of the ai world summit 2025 / 2026, the takeaway is simple: AI-first companies are being judged on execution, not intent, and Biopeak’s clinic expansion plus continued investment into diagnostics and proprietary AI tools is a clear execution signal. As we prepare programming across ai world organisation events and ai conferences by ai world, we’ll continue spotlighting startups that pair AI capabilities with disciplined operations—because that’s where durable value gets built.